Skip to content

Shaheen, Collins Issue Joint Statement on Novo Nordisk’s Decision to Reduce Insulin Prices

Shaheen and Collins lead the bipartisan INSULIN Act, which would comprehensively cut costs of the lifesaving drug.

(Washington, DC) – U.S. Senators Jeanne Shaheen (D-NH) and Susan Collins (R-ME), co-chairs of the Senate Diabetes Caucus, issued the following statement in response to drug maker Novo Nordisk’s announcement that it will cut the list prices for its commonly prescribed insulin medication by 75 percent. Shaheen and Collins have long led action in the U.S. Senate to reduce insulin prices and spearhead the bipartisan INSULIN Act, their bill to comprehensively cut costs of the lifesaving drug. 

“We commend Novo Nordisk for heeding calls from patients, families, advocates, lawmakers and Americans across the country for doing their part to lower the cost of insulin. We are encouraged by Novo Nordisk’s actions, as we were by Lilly earlier this month, and encourage other manufacturers to respond by joining those in their industry who are committed to bringing this lifesaving drug within reach for patients who need it,” said the Senators. “But there is much more work to be done to comprehensively and permanently address the skyrocketing prices of insulin, which is why we will soon introduce our legislation to break down the cost-barrier to care for millions of more Americans.”   

Over 37 million Americans have diabetes and an estimated 88 million more may be at risk of developing the disease.